article thumbnail

Exploring NMDA Antagonists for MDD

Psychiatric Times

References 1. Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder. After hitting roadblocks and not seeing improvement, Elpidio told attendees these agents helped her feel like “I’m really doing my job.” For more coverage of the Southern California Meeting, visit PsychiatricTimes.com.

article thumbnail

Gerald Maguire, MD, Provides Tips for Differentiating Bipolar Depression From MDD

Psychiatric Times

References 1. Most of our agents that we talk about as mood stabilizers may be effective in preventing a manic episode or treating mania or mixed states,” Maguire said. Our options are more limited when it comes to bipolar depression, and we do have some agents that are FDA approved specifically for bipolar depression.”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

sNDA Submitted: Lumateperone for the Prevention of Relapse in Schizophrenia

Psychiatric Times

An sNDA for Caplyta as an adjunctive treatment for adults with major depressive disorder (MDD) is also currently under FDA review, submitted back in December 2024. References 1. points (effect size 0.61) in study 501 and 4.5 points (effect size 0.56) vs placebo in study 502. Supplemental new drug application submitted to U.S.

article thumbnail

COMP360 Psilocybin for Treatment-Resistant Depression: Positive Phase 3 Efficacy Data

Psychiatric Times

References 1. After the FDA rejection of Lykos Therapeutics’ midomafetamine (MDMA)-assisted psychotherapy tempered excitement for psychedelic therapeutics, 2 this positive data could generate new momentum. News release. June 23, 2025.

article thumbnail

Major Depressive Disorder Research Roundup: July 25, 2025

Psychiatric Times

Reference Godfrey K, Douglass H, Erritzoe D, et al. The role of GABA, glutamate, and Glx levels in treatment of major depressive disorder: a systematic review and meta-analysis. Reference Shah MR, Jampa A, Kaur M, et al. Transcranial magnetic stimulation for major depressive disorder in pregnancy: a literature review.

article thumbnail

Using Serum Drug Levels

Psychiatric Times

Ultimately, what is clinically important in assessing a drug’s risk/benefit for a patient is the serum level using an established reference range with prespecified criteria to create a meaningful and reproducible result. 11 References 1. Despite this, this testing continues to be underutilized in clinical practice for unclear reasons.

article thumbnail

Tardive Dyskinesia: Treat Functional Impairment, Not the AIMS Score

Psychiatric Times

References 1. Dr Miller is Medical Director, Brain Health, Exeter, New Hampshire; Editor in Chief, Psychiatric Times ; Staff Psychiatrist, Seacoast Mental Health Center, Exeter; Consulting Psychiatrist, Insight Meditation Society, Barre, Massachusetts. Griffiths K, Won Y, Lee Z, et al. BMC Psychiatry. 2025;25(1):407.